Quantitative analysis for Palisade Bio, Inc. (PALI) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Hold (50.0) (grade C). Gem alpha score: 43.0. 28 signals analyzed (25 differentiated alt-data).
PALI stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-30 | $2.03 | $1.94 | $2.00 |
| 2026-05-12 | $1.98 | $1.89 | $1.92 |
| 2026-05-22 | $2.07 | $1.95 | $1.95 |
| 2026-06-04 | $2.06 | $1.89 | $1.93 |
| 2026-06-16 | $1.81 | $1.65 | $1.78 |
| 2026-06-29 | $2.27 | $1.91 | $2.23 |
| 2026-07-10 | $1.99 | $1.87 | $1.96 |
| 2026-07-22 | $1.99 | $1.88 | $1.90 |
| 2026-08-03 | $1.97 | $1.89 | $1.94 |
| 2026-08-13 | $2.15 | $1.98 | $2.15 |
| 2026-08-25 | $2.10 | $1.98 | $2.07 |
| 2026-09-04 | $2.12 | $2.00 | $2.09 |
How Palisade Bio, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| AUNA | Auna S.A. | $324M | — |
| LCTX | Lineage Cell Therapeutics, Inc. | $322M | — |
| CABA | Cabaletta Bio, Inc. | $331M | — |
| NMRA | Neumora Therapeutics, Inc. Common Stock | $319M | — |
View all Health Care stocks by valuation and signals →
Palisade Bio, Inc. (PALI) scores Hold (50.0), and the composite conceals a 82-point disagreement between its dimensions. It is strongest on technicals at 82 and valuation at 72, and weakest on competitive moat at 1 and AI Alpha (gem) at 0. A stock can carry technicals that high while AI Alpha (gem) sits at 0; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| technicals | 82 |
| valuation | 72 |
| analyst consensus | 66 |
| earnings quality | 61 |
| competitive moat | 1 |
| AI Alpha (gem) | 0 |
StoQuant analyzes 28 signals (25 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Palisade Bio, Inc. (PALI): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/PALI"><img src="https://stoquant.com/badge/PALI.svg" alt="Palisade Bio, Inc. (PALI) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.